Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Pranlukast Market

ID: MRFR/HC/25467-HCR
100 Pages
Rahul Gotadki
Last Updated: April 06, 2026

Pranlukast Market Research Report By Treatment Type (Asthma, Chronic Obstructive Pulmonary Disease (COPD)), By Drug Formulation (Tablets, Suspension, Inhalers), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Dose Strength (75 mg, 150 mg, 300 mg) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Pranlukast Market Infographic
Purchase Options
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Healthcare, BY Treatment Type (USD Billion)
  49.     4.1.1 Asthma
  50.     4.1.2 Chronic Obstructive Pulmonary Disease (COPD)
  51.   4.2 Healthcare, BY Drug Formulation (USD Billion)
  52.     4.2.1 Tablets
  53.     4.2.2 Suspension
  54.     4.2.3 Inhalers
  55.   4.3 Healthcare, BY Distribution Channel (USD Billion)
  56.     4.3.1 Hospital Pharmacies
  57.     4.3.2 Retail Pharmacies
  58.     4.3.3 Online Pharmacies
  59.   4.4 Healthcare, BY Dose Strength (USD Billion)
  60.     4.4.1 75 mg
  61.     4.4.2 150 mg
  62.     4.4.3 300 mg
  63.   4.5 Healthcare, BY Region (USD Billion)
  64.     4.5.1 North America
  65.       4.5.1.1 US
  66.       4.5.1.2 Canada
  67.     4.5.2 Europe
  68.       4.5.2.1 Germany
  69.       4.5.2.2 UK
  70.       4.5.2.3 France
  71.       4.5.2.4 Russia
  72.       4.5.2.5 Italy
  73.       4.5.2.6 Spain
  74.       4.5.2.7 Rest of Europe
  75.     4.5.3 APAC
  76.       4.5.3.1 China
  77.       4.5.3.2 India
  78.       4.5.3.3 Japan
  79.       4.5.3.4 South Korea
  80.       4.5.3.5 Malaysia
  81.       4.5.3.6 Thailand
  82.       4.5.3.7 Indonesia
  83.       4.5.3.8 Rest of APAC
  84.     4.5.4 South America
  85.       4.5.4.1 Brazil
  86.       4.5.4.2 Mexico
  87.       4.5.4.3 Argentina
  88.       4.5.4.4 Rest of South America
  89.     4.5.5 MEA
  90.       4.5.5.1 GCC Countries
  91.       4.5.5.2 South Africa
  92.       4.5.5.3 Rest of MEA
  93. 5 SECTION V: COMPETITIVE ANALYSIS
  94.   5.1 Competitive Landscape
  95.     5.1.1 Overview
  96.     5.1.2 Competitive Analysis
  97.     5.1.3 Market share Analysis
  98.     5.1.4 Major Growth Strategy in the Healthcare
  99.     5.1.5 Competitive Benchmarking
  100.     5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  101.     5.1.7 Key developments and growth strategies
  102.       5.1.7.1 New Product Launch/Service Deployment
  103.       5.1.7.2 Merger & Acquisitions
  104.       5.1.7.3 Joint Ventures
  105.     5.1.8 Major Players Financial Matrix
  106.       5.1.8.1 Sales and Operating Income
  107.       5.1.8.2 Major Players R&D Expenditure. 2023
  108.   5.2 Company Profiles
  109.     5.2.1 Mylan (US)
  110.       5.2.1.1 Financial Overview
  111.       5.2.1.2 Products Offered
  112.       5.2.1.3 Key Developments
  113.       5.2.1.4 SWOT Analysis
  114.       5.2.1.5 Key Strategies
  115.     5.2.2 Teva Pharmaceuticals (IL)
  116.       5.2.2.1 Financial Overview
  117.       5.2.2.2 Products Offered
  118.       5.2.2.3 Key Developments
  119.       5.2.2.4 SWOT Analysis
  120.       5.2.2.5 Key Strategies
  121.     5.2.3 Cipla (IN)
  122.       5.2.3.1 Financial Overview
  123.       5.2.3.2 Products Offered
  124.       5.2.3.3 Key Developments
  125.       5.2.3.4 SWOT Analysis
  126.       5.2.3.5 Key Strategies
  127.     5.2.4 Sun Pharmaceutical Industries (IN)
  128.       5.2.4.1 Financial Overview
  129.       5.2.4.2 Products Offered
  130.       5.2.4.3 Key Developments
  131.       5.2.4.4 SWOT Analysis
  132.       5.2.4.5 Key Strategies
  133.     5.2.5 Aurobindo Pharma (IN)
  134.       5.2.5.1 Financial Overview
  135.       5.2.5.2 Products Offered
  136.       5.2.5.3 Key Developments
  137.       5.2.5.4 SWOT Analysis
  138.       5.2.5.5 Key Strategies
  139.     5.2.6 Hikma Pharmaceuticals (GB)
  140.       5.2.6.1 Financial Overview
  141.       5.2.6.2 Products Offered
  142.       5.2.6.3 Key Developments
  143.       5.2.6.4 SWOT Analysis
  144.       5.2.6.5 Key Strategies
  145.     5.2.7 Sandoz (CH)
  146.       5.2.7.1 Financial Overview
  147.       5.2.7.2 Products Offered
  148.       5.2.7.3 Key Developments
  149.       5.2.7.4 SWOT Analysis
  150.       5.2.7.5 Key Strategies
  151.     5.2.8 Zydus Cadila (IN)
  152.       5.2.8.1 Financial Overview
  153.       5.2.8.2 Products Offered
  154.       5.2.8.3 Key Developments
  155.       5.2.8.4 SWOT Analysis
  156.       5.2.8.5 Key Strategies
  157.   5.3 Appendix
  158.     5.3.1 References
  159.     5.3.2 Related Reports
  160. 6 LIST OF FIGURES
  161.   6.1 MARKET SYNOPSIS
  162.   6.2 NORTH AMERICA MARKET ANALYSIS
  163.   6.3 US MARKET ANALYSIS BY TREATMENT TYPE
  164.   6.4 US MARKET ANALYSIS BY DRUG FORMULATION
  165.   6.5 US MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  166.   6.6 US MARKET ANALYSIS BY DOSE STRENGTH
  167.   6.7 CANADA MARKET ANALYSIS BY TREATMENT TYPE
  168.   6.8 CANADA MARKET ANALYSIS BY DRUG FORMULATION
  169.   6.9 CANADA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  170.   6.10 CANADA MARKET ANALYSIS BY DOSE STRENGTH
  171.   6.11 EUROPE MARKET ANALYSIS
  172.   6.12 GERMANY MARKET ANALYSIS BY TREATMENT TYPE
  173.   6.13 GERMANY MARKET ANALYSIS BY DRUG FORMULATION
  174.   6.14 GERMANY MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  175.   6.15 GERMANY MARKET ANALYSIS BY DOSE STRENGTH
  176.   6.16 UK MARKET ANALYSIS BY TREATMENT TYPE
  177.   6.17 UK MARKET ANALYSIS BY DRUG FORMULATION
  178.   6.18 UK MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  179.   6.19 UK MARKET ANALYSIS BY DOSE STRENGTH
  180.   6.20 FRANCE MARKET ANALYSIS BY TREATMENT TYPE
  181.   6.21 FRANCE MARKET ANALYSIS BY DRUG FORMULATION
  182.   6.22 FRANCE MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  183.   6.23 FRANCE MARKET ANALYSIS BY DOSE STRENGTH
  184.   6.24 RUSSIA MARKET ANALYSIS BY TREATMENT TYPE
  185.   6.25 RUSSIA MARKET ANALYSIS BY DRUG FORMULATION
  186.   6.26 RUSSIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  187.   6.27 RUSSIA MARKET ANALYSIS BY DOSE STRENGTH
  188.   6.28 ITALY MARKET ANALYSIS BY TREATMENT TYPE
  189.   6.29 ITALY MARKET ANALYSIS BY DRUG FORMULATION
  190.   6.30 ITALY MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  191.   6.31 ITALY MARKET ANALYSIS BY DOSE STRENGTH
  192.   6.32 SPAIN MARKET ANALYSIS BY TREATMENT TYPE
  193.   6.33 SPAIN MARKET ANALYSIS BY DRUG FORMULATION
  194.   6.34 SPAIN MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  195.   6.35 SPAIN MARKET ANALYSIS BY DOSE STRENGTH
  196.   6.36 REST OF EUROPE MARKET ANALYSIS BY TREATMENT TYPE
  197.   6.37 REST OF EUROPE MARKET ANALYSIS BY DRUG FORMULATION
  198.   6.38 REST OF EUROPE MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  199.   6.39 REST OF EUROPE MARKET ANALYSIS BY DOSE STRENGTH
  200.   6.40 APAC MARKET ANALYSIS
  201.   6.41 CHINA MARKET ANALYSIS BY TREATMENT TYPE
  202.   6.42 CHINA MARKET ANALYSIS BY DRUG FORMULATION
  203.   6.43 CHINA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  204.   6.44 CHINA MARKET ANALYSIS BY DOSE STRENGTH
  205.   6.45 INDIA MARKET ANALYSIS BY TREATMENT TYPE
  206.   6.46 INDIA MARKET ANALYSIS BY DRUG FORMULATION
  207.   6.47 INDIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  208.   6.48 INDIA MARKET ANALYSIS BY DOSE STRENGTH
  209.   6.49 JAPAN MARKET ANALYSIS BY TREATMENT TYPE
  210.   6.50 JAPAN MARKET ANALYSIS BY DRUG FORMULATION
  211.   6.51 JAPAN MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  212.   6.52 JAPAN MARKET ANALYSIS BY DOSE STRENGTH
  213.   6.53 SOUTH KOREA MARKET ANALYSIS BY TREATMENT TYPE
  214.   6.54 SOUTH KOREA MARKET ANALYSIS BY DRUG FORMULATION
  215.   6.55 SOUTH KOREA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  216.   6.56 SOUTH KOREA MARKET ANALYSIS BY DOSE STRENGTH
  217.   6.57 MALAYSIA MARKET ANALYSIS BY TREATMENT TYPE
  218.   6.58 MALAYSIA MARKET ANALYSIS BY DRUG FORMULATION
  219.   6.59 MALAYSIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  220.   6.60 MALAYSIA MARKET ANALYSIS BY DOSE STRENGTH
  221.   6.61 THAILAND MARKET ANALYSIS BY TREATMENT TYPE
  222.   6.62 THAILAND MARKET ANALYSIS BY DRUG FORMULATION
  223.   6.63 THAILAND MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  224.   6.64 THAILAND MARKET ANALYSIS BY DOSE STRENGTH
  225.   6.65 INDONESIA MARKET ANALYSIS BY TREATMENT TYPE
  226.   6.66 INDONESIA MARKET ANALYSIS BY DRUG FORMULATION
  227.   6.67 INDONESIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  228.   6.68 INDONESIA MARKET ANALYSIS BY DOSE STRENGTH
  229.   6.69 REST OF APAC MARKET ANALYSIS BY TREATMENT TYPE
  230.   6.70 REST OF APAC MARKET ANALYSIS BY DRUG FORMULATION
  231.   6.71 REST OF APAC MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  232.   6.72 REST OF APAC MARKET ANALYSIS BY DOSE STRENGTH
  233.   6.73 SOUTH AMERICA MARKET ANALYSIS
  234.   6.74 BRAZIL MARKET ANALYSIS BY TREATMENT TYPE
  235.   6.75 BRAZIL MARKET ANALYSIS BY DRUG FORMULATION
  236.   6.76 BRAZIL MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  237.   6.77 BRAZIL MARKET ANALYSIS BY DOSE STRENGTH
  238.   6.78 MEXICO MARKET ANALYSIS BY TREATMENT TYPE
  239.   6.79 MEXICO MARKET ANALYSIS BY DRUG FORMULATION
  240.   6.80 MEXICO MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  241.   6.81 MEXICO MARKET ANALYSIS BY DOSE STRENGTH
  242.   6.82 ARGENTINA MARKET ANALYSIS BY TREATMENT TYPE
  243.   6.83 ARGENTINA MARKET ANALYSIS BY DRUG FORMULATION
  244.   6.84 ARGENTINA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  245.   6.85 ARGENTINA MARKET ANALYSIS BY DOSE STRENGTH
  246.   6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT TYPE
  247.   6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY DRUG FORMULATION
  248.   6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  249.   6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY DOSE STRENGTH
  250.   6.90 MEA MARKET ANALYSIS
  251.   6.91 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT TYPE
  252.   6.92 GCC COUNTRIES MARKET ANALYSIS BY DRUG FORMULATION
  253.   6.93 GCC COUNTRIES MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  254.   6.94 GCC COUNTRIES MARKET ANALYSIS BY DOSE STRENGTH
  255.   6.95 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT TYPE
  256.   6.96 SOUTH AFRICA MARKET ANALYSIS BY DRUG FORMULATION
  257.   6.97 SOUTH AFRICA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  258.   6.98 SOUTH AFRICA MARKET ANALYSIS BY DOSE STRENGTH
  259.   6.99 REST OF MEA MARKET ANALYSIS BY TREATMENT TYPE
  260.   6.100 REST OF MEA MARKET ANALYSIS BY DRUG FORMULATION
  261.   6.101 REST OF MEA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
  262.   6.102 REST OF MEA MARKET ANALYSIS BY DOSE STRENGTH
  263.   6.103 KEY BUYING CRITERIA OF HEALTHCARE
  264.   6.104 RESEARCH PROCESS OF MRFR
  265.   6.105 DRO ANALYSIS OF HEALTHCARE
  266.   6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
  267.   6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
  268.   6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
  269.   6.109 HEALTHCARE, BY TREATMENT TYPE, 2024 (% SHARE)
  270.   6.110 HEALTHCARE, BY TREATMENT TYPE, 2024 TO 2035 (USD Billion)
  271.   6.111 HEALTHCARE, BY DRUG FORMULATION, 2024 (% SHARE)
  272.   6.112 HEALTHCARE, BY DRUG FORMULATION, 2024 TO 2035 (USD Billion)
  273.   6.113 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
  274.   6.114 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Billion)
  275.   6.115 HEALTHCARE, BY DOSE STRENGTH, 2024 (% SHARE)
  276.   6.116 HEALTHCARE, BY DOSE STRENGTH, 2024 TO 2035 (USD Billion)
  277.   6.117 BENCHMARKING OF MAJOR COMPETITORS
  278. 7 LIST OF TABLES
  279.   7.1 LIST OF ASSUMPTIONS
  280.     7.1.1
  281.   7.2 North America MARKET SIZE ESTIMATES; FORECAST
  282.     7.2.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  283.     7.2.2 BY DRUG FORMULATION, 2025-2035 (USD Billion)
  284.     7.2.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  285.     7.2.4 BY DOSE STRENGTH, 2025-2035 (USD Billion)
  286.   7.3 US MARKET SIZE ESTIMATES; FORECAST
  287.     7.3.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  288.     7.3.2 BY DRUG FORMULATION, 2025-2035 (USD Billion)
  289.     7.3.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  290.     7.3.4 BY DOSE STRENGTH, 2025-2035 (USD Billion)
  291.   7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  292.     7.4.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  293.     7.4.2 BY DRUG FORMULATION, 2025-2035 (USD Billion)
  294.     7.4.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  295.     7.4.4 BY DOSE STRENGTH, 2025-2035 (USD Billion)
  296.   7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  297.     7.5.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  298.     7.5.2 BY DRUG FORMULATION, 2025-2035 (USD Billion)
  299.     7.5.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  300.     7.5.4 BY DOSE STRENGTH, 2025-2035 (USD Billion)
  301.   7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  302.     7.6.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  303.     7.6.2 BY DRUG FORMULATION, 2025-2035 (USD Billion)
  304.     7.6.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  305.     7.6.4 BY DOSE STRENGTH, 2025-2035 (USD Billion)
  306.   7.7 UK MARKET SIZE ESTIMATES; FORECAST
  307.     7.7.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  308.     7.7.2 BY DRUG FORMULATION, 2025-2035 (USD Billion)
  309.     7.7.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  310.     7.7.4 BY DOSE STRENGTH, 2025-2035 (USD Billion)
  311.   7.8 France MARKET SIZE ESTIMATES; FORECAST
  312.     7.8.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  313.     7.8.2 BY DRUG FORMULATION, 2025-2035 (USD Billion)
  314.     7.8.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  315.     7.8.4 BY DOSE STRENGTH, 2025-2035 (USD Billion)
  316.   7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  317.     7.9.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  318.     7.9.2 BY DRUG FORMULATION, 2025-2035 (USD Billion)
  319.     7.9.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  320.     7.9.4 BY DOSE STRENGTH, 2025-2035 (USD Billion)
  321.   7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  322.     7.10.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  323.     7.10.2 BY DRUG FORMULATION, 2025-2035 (USD Billion)
  324.     7.10.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  325.     7.10.4 BY DOSE STRENGTH, 2025-2035 (USD Billion)
  326.   7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  327.     7.11.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  328.     7.11.2 BY DRUG FORMULATION, 2025-2035 (USD Billion)
  329.     7.11.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  330.     7.11.4 BY DOSE STRENGTH, 2025-2035 (USD Billion)
  331.   7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  332.     7.12.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  333.     7.12.2 BY DRUG FORMULATION, 2025-2035 (USD Billion)
  334.     7.12.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  335.     7.12.4 BY DOSE STRENGTH, 2025-2035 (USD Billion)
  336.   7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  337.     7.13.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  338.     7.13.2 BY DRUG FORMULATION, 2025-2035 (USD Billion)
  339.     7.13.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  340.     7.13.4 BY DOSE STRENGTH, 2025-2035 (USD Billion)
  341.   7.14 China MARKET SIZE ESTIMATES; FORECAST
  342.     7.14.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  343.     7.14.2 BY DRUG FORMULATION, 2025-2035 (USD Billion)
  344.     7.14.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  345.     7.14.4 BY DOSE STRENGTH, 2025-2035 (USD Billion)
  346.   7.15 India MARKET SIZE ESTIMATES; FORECAST
  347.     7.15.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  348.     7.15.2 BY DRUG FORMULATION, 2025-2035 (USD Billion)
  349.     7.15.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  350.     7.15.4 BY DOSE STRENGTH, 2025-2035 (USD Billion)
  351.   7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  352.     7.16.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  353.     7.16.2 BY DRUG FORMULATION, 2025-2035 (USD Billion)
  354.     7.16.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  355.     7.16.4 BY DOSE STRENGTH, 2025-2035 (USD Billion)
  356.   7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  357.     7.17.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  358.     7.17.2 BY DRUG FORMULATION, 2025-2035 (USD Billion)
  359.     7.17.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  360.     7.17.4 BY DOSE STRENGTH, 2025-2035 (USD Billion)
  361.   7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  362.     7.18.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  363.     7.18.2 BY DRUG FORMULATION, 2025-2035 (USD Billion)
  364.     7.18.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  365.     7.18.4 BY DOSE STRENGTH, 2025-2035 (USD Billion)
  366.   7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  367.     7.19.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  368.     7.19.2 BY DRUG FORMULATION, 2025-2035 (USD Billion)
  369.     7.19.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  370.     7.19.4 BY DOSE STRENGTH, 2025-2035 (USD Billion)
  371.   7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  372.     7.20.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  373.     7.20.2 BY DRUG FORMULATION, 2025-2035 (USD Billion)
  374.     7.20.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  375.     7.20.4 BY DOSE STRENGTH, 2025-2035 (USD Billion)
  376.   7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  377.     7.21.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  378.     7.21.2 BY DRUG FORMULATION, 2025-2035 (USD Billion)
  379.     7.21.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  380.     7.21.4 BY DOSE STRENGTH, 2025-2035 (USD Billion)
  381.   7.22 South America MARKET SIZE ESTIMATES; FORECAST
  382.     7.22.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  383.     7.22.2 BY DRUG FORMULATION, 2025-2035 (USD Billion)
  384.     7.22.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  385.     7.22.4 BY DOSE STRENGTH, 2025-2035 (USD Billion)
  386.   7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  387.     7.23.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  388.     7.23.2 BY DRUG FORMULATION, 2025-2035 (USD Billion)
  389.     7.23.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  390.     7.23.4 BY DOSE STRENGTH, 2025-2035 (USD Billion)
  391.   7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  392.     7.24.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  393.     7.24.2 BY DRUG FORMULATION, 2025-2035 (USD Billion)
  394.     7.24.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  395.     7.24.4 BY DOSE STRENGTH, 2025-2035 (USD Billion)
  396.   7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  397.     7.25.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  398.     7.25.2 BY DRUG FORMULATION, 2025-2035 (USD Billion)
  399.     7.25.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  400.     7.25.4 BY DOSE STRENGTH, 2025-2035 (USD Billion)
  401.   7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  402.     7.26.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  403.     7.26.2 BY DRUG FORMULATION, 2025-2035 (USD Billion)
  404.     7.26.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  405.     7.26.4 BY DOSE STRENGTH, 2025-2035 (USD Billion)
  406.   7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  407.     7.27.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  408.     7.27.2 BY DRUG FORMULATION, 2025-2035 (USD Billion)
  409.     7.27.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  410.     7.27.4 BY DOSE STRENGTH, 2025-2035 (USD Billion)
  411.   7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  412.     7.28.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  413.     7.28.2 BY DRUG FORMULATION, 2025-2035 (USD Billion)
  414.     7.28.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  415.     7.28.4 BY DOSE STRENGTH, 2025-2035 (USD Billion)
  416.   7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  417.     7.29.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  418.     7.29.2 BY DRUG FORMULATION, 2025-2035 (USD Billion)
  419.     7.29.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  420.     7.29.4 BY DOSE STRENGTH, 2025-2035 (USD Billion)
  421.   7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  422.     7.30.1 BY TREATMENT TYPE, 2025-2035 (USD Billion)
  423.     7.30.2 BY DRUG FORMULATION, 2025-2035 (USD Billion)
  424.     7.30.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
  425.     7.30.4 BY DOSE STRENGTH, 2025-2035 (USD Billion)
  426.   7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  427.     7.31.1
  428.   7.32 ACQUISITION/PARTNERSHIP
  429.     7.32.1

Healthcare Market Segmentation

Healthcare By Treatment Type (USD Billion, 2025-2035)

  • Asthma
  • Chronic Obstructive Pulmonary Disease (COPD)

Healthcare By Drug Formulation (USD Billion, 2025-2035)

  • Tablets
  • Suspension
  • Inhalers

Healthcare By Distribution Channel (USD Billion, 2025-2035)

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Healthcare By Dose Strength (USD Billion, 2025-2035)

  • 75 mg
  • 150 mg
  • 300 mg

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions